

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

RECEIVED
SECRETARY OF THE SEN
PUBLIC RECORDS

03 FEB 12 PM 12:1

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Clark & Weinstock			
2. Registrant Address <input type="checkbox"/> Check if different than previously reported Address 1775 I Street NW, Ste 700 City Washington, State/Zip (or Country) DC 20006			
3. Principal Place of Business (if different from line 2) City New York, State/Zip (or Country) NY 10017			
4. Contact Name Lisa Hayes	Telephone 202-261-4025	E-mail (optional) lisa@cwdc.com	5. Senate ID # 9443--595
7. Client Name <input type="checkbox"/> Self PhRMA			6. House ID # 316-98054

TYPE OF REPORT 8. Year 2002 Midyear (January 1-June 30) ☐ OR Year End (July 1-De

9. Check if this filing amends a previously filed version of this report ☐

10. Check if this is a Termination Report ☐ >> Termination Date _____

11. No Lobby

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
INCOME relating to lobbying activities for this reporting period was: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input checked="" type="checkbox"/> >> \$ <u>\$180,000.00</u> <div style="text-align: right;">Income (nearest \$20,000)</div> Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	EXPENSES relating to lobbying activities for this rep period were: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input type="checkbox"/> >> \$ _____ <div style="text-align: right;">Expenses (nearest \$</div> 14. REPORTING METHOD. Check box to indicat accounting method. See instructions for description of <input type="checkbox"/> Method A. Reporting amounts using LDA definiti <input type="checkbox"/> Method B. Reporting amounts under section 603 the Internal Revenue Code <input type="checkbox"/> Method C. Reporting amounts under section 162 Internal Revenue Code

Signature _____ Date 2/10/03

Printed Name and Title Vin Weber - Partner F

Registrant Name: Clark & WeinstockClient Name: PhRMA

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)16. Specific Lobbying issues
see attached page

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

Department of Health & Human Services
Executive Office of the President
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bieron, Brian	Policy Director, House Rules Committee
Bonham, Kent	Policy Director for Sen. Chuck Hagel (R-NE)
Fazio, Vic	
Glover Weiss, Juleanna	Press Secretary to the Vice President
Godes, Niles	Chief of Staff to Sen. Byron Dorgan (D-ND)
Gribbin, Dave	
Kutler, Ed	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature _____ Date 2/10/03

Printed Name and Title Vin Weber - Partner F

Registrant Name: Clark & WeinstockClient Name: PhRMA

Item	Description	Data
16	Lobbying Issues	<p>Lobbied for Medicare reform and to provide prescription drug coverage for seniors:</p> <p>H.R.5263 : Making appropriations for Agriculture, Rural Development, Food and Drug Administration, and Related Agencies programs for the fiscal year ending September 30, 2003, and for other purposes.</p> <p>HR 4954 To amend title XVIII of the Social Security Act to provide for a voluntary program for prescription drug coverage under the Medicare Program, to modify and reform payments and the regulatory structure of the Medicare Program, and for other purposes</p> <p>H.R. 2330, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act 2002</p> <p>H. AMDT. 140, Brown amendment, makes available an additional 2.5 million dollars for the Food and Drug Administration Office of Generic Drugs</p> <p>H. AMDT. 141, Brown amendment, allocates 5 million dollars to carry out the FDA's antibiotic resistance plan</p> <p>H. AMDT. 147, Sanders amendment, amendment sought to prohibit use of funds for enforcement of Section 801 (d) (1) of the Federal Food, Drug and Cosmetic Act</p> <p>H. AMDT. 150, Gutknecht amendment, prohibits use of funds in the bill for the purpose of preventing an individual who is not in the business of importing prescription drugs, from importing drugs that (1) appear to be FDA approved, do not appear to be narcotic drugs, and (3) appear to be manufactured, prepared, propagated, compounded, or processed in an establishment pursuant to the Federal Food, Drug and Cosmetic Act</p> <p>H. AMDT. 163, Brown amendment, increases the funding by one million dollars of responsibilities of the FDA with respect to abbreviated applications for the approval of new drugs</p> <p>H. AMDT. 164, Allen amendment, to prohibit use of funds for approval of new drug applications without disclosure of the cost of research and development of new drug and what portion of that cost is made up with public funding</p> <p>S. 2729, Medicare Prescription Drug Benefit Bill, relating to prescription drug coverage.</p> <p>Intellectual Property and Patent issues including the following:</p> <p>S. 812, Greater Access to Affordable Pharmaceuticals Act of 2001, to amend the federal Food, Drug and Cosmetic Act to provide greater access to affordable pharmaceuticals</p> <p>S. 1229, To amend the Federal Food, Drug, and Cosmetic Act to permit individuals to import prescription drugs in limited circumstances; worked on the Dorgan-Wellstone amendments dealing with intellectual property issues</p>

Registrant Name: Clark & Weinstock

Client Name: PhRMA

Item	Description	Data
18a	Lobbyist Name	Mathews, Jim
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Morrison, Timothy
18b	Covered Official Position	Associate Director, Presidential Personnel
18c	New Lobbyist	No
18a	Lobbyist Name	Stach, Deirdre
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Stuart, Sandi
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Weber, Vin
18b	Covered Official Position	
18c	New Lobbyist	No

Registrant Name: Clark & WeinstockClient Name: PhRMA

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MED (one per page)

16. Specific Lobbying issues
See attached page.

17. House(s) of Congress and Federal agencies contacted
Department of Health & Human Services
Executive Office of the President
House of Representatives
Senate

☐ Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bieron, Brian	Policy Director, House Rules Committee
Bonham, Kent	Policy Director for Sen. Chuck Hagel (R-NE)
Fazio, Vic	
Glover Weiss, Juleanna	Press Secretary to the Vice President
Godes, Niles	Chief of Staff to Sen. Byron Dorgan (D-ND)
Kutler, Ed	
Mathews, Jim	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature _____ Date 2/10/03

Printed Name and Title Vin Weber - Partner P

Registrant Name: Clark & WeinstockClient Name: PhRMA

Item	Description	Data
16	Lobbying Issues	<p>Lobbied for Medicare reform and to provide prescription drug coverage for seniors:</p> <p>H.R.5263 : Making appropriations for Agriculture, Rural Development, Food and Drug Administration, and Related Agencies programs for the fiscal year ending September 30, 2003, and for other purposes.</p> <p>HR 4954 To amend title XVIII of the Social Security Act to provide for a voluntary program for prescription drug coverage under the Medicare Program, to modify and reform payments and the regulatory structure of the Medicare Program, and for other purposes</p> <p>H.R. 2330, Agriculture, Rural Development, Food and Drug Administration, and related agencies Appropriations Act 2002</p> <p>H. AMDT. 140, Brown amendment, makes available an additional 2.5 million dollars for the Food and Drug Administration Office of Generic Drugs</p> <p>H. AMDT. 141, Brown amendment, allocates 5 million dollars to carry out the FDA's antibiotic resistance plan</p> <p>H. AMDT. 147, Sanders amendment, amendment sought to prohibit use of funds for enforcement of Section 801 (d) (1) of the Federal Food, Drug and Cosmetic Act</p> <p>H. AMDT. 150, Gutmacht amendment, prohibits use of funds in the bill for the purpose of preventing an individual who is not in the business of importing prescription drugs, from importing drugs that (1) appear to be FDA approved, do not appear to be narcotic drugs, and (3) appear to be manufactured, prepared, propagated, compounded, or processed in an establishment pursuant to the Federal Food, Drug and Cosmetic Act</p> <p>H. AMDT. 163, Brown amendment, increases the funding by one million dollars of responsibilities of the FDA with respect to abbreviated applications for the approval of new drugs</p> <p>H. AMDT. 164, Allen amendment, to prohibit use of funds for approval of new drug applications without disclosure of the cost of research and development of new drug and what portion of that cost is made up with public funding</p> <p>S. 2729, Medicare Prescription Drug Benefit Bill, relating to prescription drug coverage.</p> <p>Intellectual Property and Patent issues including the following:</p> <p>S. 812, Greater Access to Affordable Pharmaceuticals Act of 2001, to amend the federal Food, Drug and Cosmetic Act to provide greater access to affordable pharmaceuticals</p> <p>S. 1229, To amend the Federal Food, Drug, and Cosmetic Act to permit individuals to import prescription drugs in limited circumstances; worked on the Dorgan-Wellstone amendments dealing with intellectual property issues</p>

}

P

Registrant Name: Clark & WeinstockClient Name: PhRMA

Item	Description	Data
18a	Lobbyist Name	Morrison, Timothy
18b	Covered Official Position	Associate Director, Presidential Personnel
18c	New Lobbyist	No
18a	Lobbyist Name	Stach, Deirdre
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Stuart, Sandi
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Weber, Vin
18b	Covered Official Position	
18c	New Lobbyist	No

|

Registrant Name: Clark & Weinstock

Client Name: PhRMA

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific Lobbying issues
see attached page

17. House(s) of Congress and Federal agencies contacted
House of Representatives
Senate

☐ Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bieron, Brian	Policy Director, House Rules Committee
Bonham, Kent	Policy Director for Sen. Chuck Hagel (R-NE)
Fazio, Vic	
Glover Weiss, Juleanna	Press Secretary to the Vice President
Godes, Niles	Chief of Staff to Sen. Byron Dorgan (D-ND)
Gribbin, Dave	
Kutler, Ed	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature _____ Date 2/10/03

Printed Name and Title Vin Weber - Partner P

Registrant Name: Clark & WeinstockClient Name: PhRMA

Item	Description	Data
16	Lobbying Issues	<p>Lobbied for Medicare reform and to provide prescription drug coverage for seniors:</p> <p>H.R.5263 : Making appropriations for Agriculture, Rural Development, Food and Drug Administration, and Related Agencies programs for the fiscal year ending September 30, 2003, and for other purposes.</p> <p>HR 4954 To amend title XVIII of the Social Security Act to provide for a voluntary program for prescription drug coverage under the Medicare Program, to modify and reform payments and the regulatory structure of the Medicare Program for other purposes</p> <p>H.R. 2330, Agriculture, Rural Development, Food and Drug Administration related agencies Appropriations Act 2002</p> <p>H. AMDT. 140, Brown amendment, makes available an additional 2.5 million dollars for the Food and Drug Administration Office of Generic Drugs</p> <p>H. AMDT. 141, Brown amendment, allocates 5 million dollars to carry out the FDA's antibiotic resistance plan</p> <p>H. AMDT. 147, Sanders amendment, amendment sought to prohibit use of funds for enforcement of Section 801 (d) (1) of the Federal Food, Drug and Cosmetic Act</p> <p>H. AMDT. 150, Gutknecht amendment, prohibits use of funds in the bill for the purpose of preventing an individual who is not in the business of importing prescription drugs, from importing drugs that (1) appear to be FDA approved, (2) do not appear to be narcotic drugs, and (3) appear to be manufactured, prepared, propagated, compounded, or processed in an establishment pursuant to the Federal Food, Drug and Cosmetic Act</p> <p>H. AMDT. 163, Brown amendment, increases the funding by one million dollars of the responsibilities of the FDA with respect to abbreviated applications for the approval of new drugs</p> <p>H. AMDT. 164, Allen amendment, to prohibit use of funds for approval of new drug applications without disclosure of the cost of research and development of new drug and what portion of that cost is made up with public funding</p>

Registrant Name: Clark & Weinstock

Client Name: PhRMA

Item	Description	Data
18a	Lobbyist Name	Mathews, Jim
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Morrison, Timothy
18b	Covered Official Position	Associate Director, Presidential Personnel
18c	New Lobbyist	No
18a	Lobbyist Name	Stach, Deirdre
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Stuart, Sandi
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Weber, Vin
18b	Covered Official Position	
18c	New Lobbyist	No

1

40

P

Registrant Name: Clark & WeinstockClient Name: PhRMA

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TRD (one per page)

16. Specific Lobbying issues
The implementation of the Doha Agreement

17. House(s) of Congress and Federal agencies contacted
House of Representatives
Office of U.S. Trade Representative
Senate


☐ Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bieron, Brian	Policy Director, House Rules Committee
Bonham, Kent	Policy Director for Sen. Chuck Hagel (R-NE)
Fazio, Vic	
Glover Weiss, Juleanna	Press Secretary to the Vice President
Godes, Niles	Chief of Staff to Sen. Byron Dorgan (D-ND)
Gribbin, Dave	
Kutler, Ed	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature  Date 2/10/03

Printed Name and Title Vin Weber - Partner P

Registrant Name: Clark & WeinstockClient Name: PhRMA

Item	Description	Data
18a	Lobbyist Name	Stach, Deirdre
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Stuart, Sandi
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Weber, Vin
18b	Covered Official Position	
18c	New Lobbyist	No

